CGEM vs RAPP
CGEM: Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases. RAPP: Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex neurological and psychiatric disorders.
Side-by-side fundamentals
| Metric | CGEM | RAPP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.65 | $41.33 | |
| Market cap as of 2026-07-23 | $1.1B | $2.1B | |
| PEG as of 2026-07-23 | -0.24 | -0.90 | RAPP lower |
| Net margin as of 2026-07-23 | -346.2% | n/a | |
| Operating margin as of 2026-07-23 | -358.8% | n/a | |
| ROE as of 2026-07-23 | -51.4% | -24.8% | RAPP higher |
| ROA as of 2026-07-23 | -47.6% | -23.4% | RAPP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.00 | 2.58 | |
| 1-year return as of 2026-07-22 close | +140.2% | +195.8% | RAPP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.